Loading clinical trials...

A Study of IBI3032 in Chinese Participants With Overweight or Obesity | Clinical Trials | Clareo Health

ACTIVE_NOT_RECRUITINGPHASE1

A Study of IBI3032 in Chinese Participants With Overweight or Obesity

A Phase 1 Clinical Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IBI3032 After Multiple Ascending Doses in Participants With Overweight or Obesity

NCT07170319•Innovent Biologics Technology Limited (Shanghai R&D Center)

View on ClinicalTrials.gov

Summary

This is a randomized, double-blind, placebo-controlled phase 1 clinical study evaluating the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of multiple ascending doses of IBI3032 in participants with overweight or obesity. It is a multiple ascending dose study in participants with overweight or obesity during the 4-week treatment period.

Eligibility

Age

18 - 65 years

Sex

ALL

Healthy Volunteers

Yes

Inclusion Criteria

•Healthy male or females, as determined by medical history
•Have safety laboratory results within normal reference ranges

Exclusion Criteria

•Have known allergies toIBI3032， glucagon-like peptide-1 (GLP-1) analogs, related compounds
•Abnormal electrocardiogram (ECG) at screening
•Significant history of or current cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrine, hematological or neurological disorders.

Locations (1)

The Frist Affiliated Hospital of Anhui Medical University

Hefei, Anhui, China

Key Dates

Start Date

September 25, 2025

Primary Completion Date

December 24, 2025

Completion Date

March 31, 2026

Last Updated

December 31, 2025

Enrollment

ACTUAL participants

Conditions

Overweight or Obesity

Interventions

IBI3032

DRUG

placebo

DRUG

A Study of IBI3032 in Chinese Healthy Participants and Participants With Overweight or Obesity

NCT07160400

Part A: Healthy Part B: Overweight or Obesity

View study

RECRUITINGPHASE1

Relative Bioavailability of First vs Second-Generation Formulations of HRS9531 Tablets in Obese or Overweight Subjects

NCT07150962

Overweight or Obesity

View study

RECRUITINGPHASE3

Semaglutide for Metabolic Intervention and Adipose Loss to Treat Atrial Fibrillation

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: December 31, 2025Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

A Study of IBI3032 in Chinese Participants With Overweight or Obesity

Inclusion Criteria

Exclusion Criteria

A Study of IBI3032 in Chinese Healthy Participants and Participants With Overweight or Obesity

Relative Bioavailability of First vs Second-Generation Formulations of HRS9531 Tablets in Obese or Overweight Subjects

Semaglutide for Metabolic Intervention and Adipose Loss to Treat Atrial Fibrillation

Weight Reduction in CLBP

A Study of BGM0504 Injection in Participants with Obesity or Overweight

Promote Weight Loss in Obese Peripheral Artery Disease (PAD) Patients to Prevent Mobility Loss